These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 8640819)

  • 1. Pharmacokinetic modulation of irinotecan and metabolites by cyclosporin A.
    Gupta E; Safa AR; Wang X; Ratain MJ
    Cancer Res; 1996 Mar; 56(6):1309-14. PubMed ID: 8640819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetic modulation of irinotecan metabolites by sulphobromophthalein in rats.
    Itoh T; Itagaki S; Sasaki K; Hirano T; Takemoto I; Iseki K
    J Pharm Pharmacol; 2004 Jun; 56(6):809-12. PubMed ID: 15231047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of P-glycoprotein inhibitor, verapamil, on oral bioavailability and pharmacokinetics of irinotecan in rats.
    Bansal T; Mishra G; Jaggi M; Khar RK; Talegaonkar S
    Eur J Pharm Sci; 2009 Mar; 36(4-5):580-90. PubMed ID: 19135530
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of P-glycoprotein modulator, cyclosporin A, on the gastrointestinal excretion of irinotecan and its metabolite SN-38 in rats.
    Arimori K; Kuroki N; Hidaka M; Iwakiri T; Yamsaki K; Okumura M; Ono H; Takamura N; Kikuchi M; Nakano M
    Pharm Res; 2003 Jun; 20(6):910-7. PubMed ID: 12817897
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of glucuronidation of SN-38, the active metabolite of irinotecan, by valproic acid and phenobarbital.
    Gupta E; Wang X; Ramirez J; Ratain MJ
    Cancer Chemother Pharmacol; 1997; 39(5):440-4. PubMed ID: 9054958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biliary transport of irinotecan and metabolites in normal and P-glycoprotein-deficient mice.
    Iyer L; Ramírez J; Shepard DR; Bingham CM; Hossfeld DK; Ratain MJ; Mayer U
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):336-41. PubMed ID: 11914914
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein.
    Sugiyama Y; Kato Y; Chu X
    Cancer Chemother Pharmacol; 1998; 42 Suppl():S44-9. PubMed ID: 9750028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
    Klein CE; Gupta E; Reid JM; Atherton PJ; Sloan JA; Pitot HC; Ratain MJ; Kastrissios H
    Clin Pharmacol Ther; 2002 Dec; 72(6):638-47. PubMed ID: 12496745
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pre-clinical evidence for altered absorption and biliary excretion of irinotecan (CPT-11) in combination with quercetin: possible contribution of P-glycoprotein.
    Bansal T; Awasthi A; Jaggi M; Khar RK; Talegaonkar S
    Life Sci; 2008 Aug; 83(7-8):250-9. PubMed ID: 18619980
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacokinetics of irinotecan and its metabolites in relation with diarrhea.
    Xie R; Mathijssen RH; Sparreboom A; Verweij J; Karlsson MO
    Clin Pharmacol Ther; 2002 Sep; 72(3):265-75. PubMed ID: 12235447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Loperamide inhibits the biliary excretion of irinotecan (CPT-11) in the rat isolated perfused liver.
    Tobin PJ; Hong Y; Seale JP; Rivory LP; McLachlan AJ
    J Pharm Pharmacol; 2005 Jan; 57(1):39-45. PubMed ID: 15638991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Biliary excretion of irinotecan and its metabolites.
    Itoh T; Takemoto I; Itagaki S; Sasaki K; Hirano T; Iseki K
    J Pharm Pharm Sci; 2004 Jan; 7(1):13-8. PubMed ID: 15144730
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatic transport, metabolism and biliary excretion of irinotecan in a cancer patient with an external bile drain.
    de Jong FA; Kitzen JJ; de Bruijn P; Verweij J; Loos WJ
    Cancer Biol Ther; 2006 Sep; 5(9):1105-10. PubMed ID: 16969123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of cyclosporin A on the pharmacokinetics and toxicities of irinotecan mediated by UGT1A1
    Qin Y; Wang N; Chen F; Han X; Zhu Y; Rang Y; Zhai X; Lu Y
    Pharmazie; 2020 May; 75(5):186-190. PubMed ID: 32393425
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influence of genetic polymorphisms in UGT1A1, UGT1A7 and UGT1A9 on the pharmacokynetics of irinotecan, SN-38 and SN-38G].
    Valenzuela Jiménez B; González Sales M; Escudero Ortiz V; Martínez Navarro E; Pérez Ruixo C; Rebollo Liceaga J; González Manzano R; Pérez Ruixo JJ
    Farm Hosp; 2013; 37(2):111-27. PubMed ID: 23789755
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Irinotecan (CPT-11) metabolism and disposition in cancer patients.
    Sparreboom A; de Jonge MJ; de Bruijn P; Brouwer E; Nooter K; Loos WJ; van Alphen RJ; Mathijssen RH; Stoter G; Verweij J
    Clin Cancer Res; 1998 Nov; 4(11):2747-54. PubMed ID: 9829738
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quantification of the impact of enzyme-inducing antiepileptic drugs on irinotecan pharmacokinetics and SN-38 exposure.
    Berg AK; Buckner JC; Galanis E; Jaeckle KA; Ames MM; Reid JM
    J Clin Pharmacol; 2015 Nov; 55(11):1303-12. PubMed ID: 25975718
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats.
    Chu XY; Kato Y; Sugiyama Y
    Drug Metab Dispos; 1999 Apr; 27(4):440-1. PubMed ID: 10101137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Food-drug interaction of (-)-epigallocatechin-3-gallate on the pharmacokinetics of irinotecan and the metabolite SN-38.
    Lin LC; Wang MN; Tsai TH
    Chem Biol Interact; 2008 Aug; 174(3):177-82. PubMed ID: 18579105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
    Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
    Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.